Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party.
- Author:
Seok Jin KIM
1
;
Soo Mee BANG
;
Yoon Seok CHOI
;
Deog Yeon JO
;
Jin Seok KIM
;
Hyewon LEE
;
Hyeon Seok EOM
;
Dok Hyun YOON
;
Cheolwon SUH
;
Je Jung LEE
;
Junshik HONG
;
Jae Hoon LEE
;
Youngil KOH
;
Kihyun KIM
;
Sung Soo YOON
;
Chang Ki MIN
Author Information
- Publication Type:Multicenter Study ; Original Article
- Keywords: Myeloma; Bendamustine; Response; Toxicity; Survival
- MeSH: Asian Continental Ancestry Group; Bendamustine Hydrochloride*; Bortezomib; Diagnosis; Disease Progression; Humans; Multiple Myeloma*; Prednisone; Retrospective Studies*; Salvage Therapy; Survival Rate
- From:Blood Research 2016;51(3):193-199
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Bendamustine may be a potential treatment option for patients with myeloma, but little is known about the utility of bendamustine as a salvage treatment, especially in Asian patients. METHODS: We performed a multicenter retrospective study of patients with relapsed or refractory myeloma who received bendamustine and prednisone. RESULTS: The records of 65 heavily pre-treated patients, who had undergone bortezomib and lenalidomide treatment (median number of previous treatments: 5), were analyzed. The median time from diagnosis to bendamustine treatment was 3.8 years, and the median patient age was 63 years (range, 38‒77 yr). The responses to the last treatment before bendamustine were refractory disease (N=52, 80%) or disease progression from partial response (N=13, 20%). Twenty-three patients responded to the treatment, with an overall response rate of 35% (23/65), and the median number of bendamustine treatment cycles was two (range, 1‒5 cycles). The median overall survival after bendamustine treatment was 5.5 months and the overall survival rate in responders to bendamustine was significantly better than that in non-responders (P=0.036). CONCLUSION: Bendamustine may be a potential salvage treatment to extend survival in a select group of heavily pre-treated patients with relapsed or refractory myeloma.
